Methods for Including Adverse Events in Economic Evaluations: Suggestions for Improvement

Inclusion of relevant effectiveness and safety outcomes in economic evaluation of health technologies is required to aid efficient healthcare decisions. Our objective was to identify the key issues related to the inclusion of adverse events (AEs) in economic evaluation and explore perspectives for g...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Value in health Ročník 27; číslo 7; s. 936 - 942
Hlavní autori:	Ghabri, Salah, Dawoud, Dalia, Drummond, Michael
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 01.07.2024
Predmet:	Adverse events Cost-Benefit Analysis - methods costs decision models Decision Support Techniques disutilities Drug-Related Side Effects and Adverse Reactions - economics economic evaluation health technology assessment Humans Internal Medicine Models, Economic Public Health Quality of Life Technology Assessment, Biomedical Terminology as Topic Uncertainty health technology assessment costs Adverse events decision models disutilities economic evaluation quality of life uncertainty
ISSN:	1098-3015, 1524-4733, 1524-4733
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Inclusion of relevant effectiveness and safety outcomes in economic evaluation of health technologies is required to aid efficient healthcare decisions. Our objective was to identify the key issues related to the inclusion of adverse events (AEs) in economic evaluation and explore perspectives for good practice recommendations to handle these issues. We focused on the frequently encountered methodological issues related to the integration of AEs in economic evaluations of health technologies. We distinguished the following elements: the incorporation of AEs in decision models, the terminology of AEs, the estimation of AEs consequences in terms of quality of life (QoL) and costs, and the exploration of the uncertainty related to the impact of AEs on the economic results. We illustrated and discussed each of the identified issues by giving health technology assessment examples. We focused on the extent to which the integration of AEs in decision models can be improved by dealing with the lack of relevant real-world safety data, estimating the consequences of AEs (eg, for costs and QoL loss), exploring the impacts of AEs that are not adequately captured in current measurement of health-related QoL, and identifying the need for development of a good terminology of relevant types of AEs to be incorporated in economic evaluation. Based on a reflection the key methodological issues related to the incorporation of adverse drug events in economic evaluations, we suggested several recommendations to serve a starting point for health technology assessment agencies and researchers to develop good research practices in this field. •Today, there are no standardized methods related to the inclusion of adverse events (AEs) in economic evaluations of health technologies. The current health technology assessment guidelines of health technologies illustrate an unmet need for improving methods for including AEs in economic evaluations.•Good research practices on improving the integration of AEs in economic evaluation are necessary and should explore specific health technology assessment recommendations (eg, decision analytic models, terminology and types of AEs, the estimation of their impacts in terms of quality of life and costs, and uncertainty).
AbstractList	Inclusion of relevant effectiveness and safety outcomes in economic evaluation of health technologies is required to aid efficient healthcare decisions. Our objective was to identify the key issues related to the inclusion of adverse events (AEs) in economic evaluation and explore perspectives for good practice recommendations to handle these issues.OBJECTIVEInclusion of relevant effectiveness and safety outcomes in economic evaluation of health technologies is required to aid efficient healthcare decisions. Our objective was to identify the key issues related to the inclusion of adverse events (AEs) in economic evaluation and explore perspectives for good practice recommendations to handle these issues.We focused on the frequently encountered methodological issues related to the integration of AEs in economic evaluations of health technologies. We distinguished the following elements: the incorporation of AEs in decision models, the terminology of AEs, the estimation of AEs consequences in terms of quality of life (QoL) and costs, and the exploration of the uncertainty related to the impact of AEs on the economic results.METHODSWe focused on the frequently encountered methodological issues related to the integration of AEs in economic evaluations of health technologies. We distinguished the following elements: the incorporation of AEs in decision models, the terminology of AEs, the estimation of AEs consequences in terms of quality of life (QoL) and costs, and the exploration of the uncertainty related to the impact of AEs on the economic results.We illustrated and discussed each of the identified issues by giving health technology assessment examples. We focused on the extent to which the integration of AEs in decision models can be improved by dealing with the lack of relevant real-world safety data, estimating the consequences of AEs (eg, for costs and QoL loss), exploring the impacts of AEs that are not adequately captured in current measurement of health-related QoL, and identifying the need for development of a good terminology of relevant types of AEs to be incorporated in economic evaluation.RESULTSWe illustrated and discussed each of the identified issues by giving health technology assessment examples. We focused on the extent to which the integration of AEs in decision models can be improved by dealing with the lack of relevant real-world safety data, estimating the consequences of AEs (eg, for costs and QoL loss), exploring the impacts of AEs that are not adequately captured in current measurement of health-related QoL, and identifying the need for development of a good terminology of relevant types of AEs to be incorporated in economic evaluation.Based on a reflection the key methodological issues related to the incorporation of adverse drug events in economic evaluations, we suggested several recommendations to serve a starting point for health technology assessment agencies and researchers to develop good research practices in this field.CONCLUSIONBased on a reflection the key methodological issues related to the incorporation of adverse drug events in economic evaluations, we suggested several recommendations to serve a starting point for health technology assessment agencies and researchers to develop good research practices in this field. Inclusion of relevant effectiveness and safety outcomes in economic evaluation of health technologies is required to aid efficient healthcare decisions. Our objective was to identify the key issues related to the inclusion of adverse events (AEs) in economic evaluation and explore perspectives for good practice recommendations to handle these issues. We focused on the frequently encountered methodological issues related to the integration of AEs in economic evaluations of health technologies. We distinguished the following elements: the incorporation of AEs in decision models, the terminology of AEs, the estimation of AEs consequences in terms of quality of life (QoL) and costs, and the exploration of the uncertainty related to the impact of AEs on the economic results. We illustrated and discussed each of the identified issues by giving health technology assessment examples. We focused on the extent to which the integration of AEs in decision models can be improved by dealing with the lack of relevant real-world safety data, estimating the consequences of AEs (eg, for costs and QoL loss), exploring the impacts of AEs that are not adequately captured in current measurement of health-related QoL, and identifying the need for development of a good terminology of relevant types of AEs to be incorporated in economic evaluation. Based on a reflection the key methodological issues related to the incorporation of adverse drug events in economic evaluations, we suggested several recommendations to serve a starting point for health technology assessment agencies and researchers to develop good research practices in this field. Inclusion of relevant effectiveness and safety outcomes in economic evaluation of health technologies is required to aid efficient healthcare decisions. Our objective was to identify the key issues related to the inclusion of adverse events (AEs) in economic evaluation and explore perspectives for good practice recommendations to handle these issues. We focused on the frequently encountered methodological issues related to the integration of AEs in economic evaluations of health technologies. We distinguished the following elements: the incorporation of AEs in decision models, the terminology of AEs, the estimation of AEs consequences in terms of quality of life (QoL) and costs, and the exploration of the uncertainty related to the impact of AEs on the economic results. We illustrated and discussed each of the identified issues by giving health technology assessment examples. We focused on the extent to which the integration of AEs in decision models can be improved by dealing with the lack of relevant real-world safety data, estimating the consequences of AEs (eg, for costs and QoL loss), exploring the impacts of AEs that are not adequately captured in current measurement of health-related QoL, and identifying the need for development of a good terminology of relevant types of AEs to be incorporated in economic evaluation. Based on a reflection the key methodological issues related to the incorporation of adverse drug events in economic evaluations, we suggested several recommendations to serve a starting point for health technology assessment agencies and researchers to develop good research practices in this field. •Today, there are no standardized methods related to the inclusion of adverse events (AEs) in economic evaluations of health technologies. The current health technology assessment guidelines of health technologies illustrate an unmet need for improving methods for including AEs in economic evaluations.•Good research practices on improving the integration of AEs in economic evaluation are necessary and should explore specific health technology assessment recommendations (eg, decision analytic models, terminology and types of AEs, the estimation of their impacts in terms of quality of life and costs, and uncertainty). AbstractObjectiveInclusion of relevant effectiveness and safety outcomes in economic evaluation of health technologies is required to aid efficient healthcare decisions. Our objective was to identify the key issues related to the inclusion of adverse events (AEs) in economic evaluation and explore perspectives for good practice recommendations to handle these issues. MethodsWe focused on the frequently encountered methodological issues related to the integration of AEs in economic evaluations of health technologies. We distinguished the following elements: the incorporation of AEs in decision models, the terminology of AEs, the estimation of AEs consequences in terms of quality of life (QoL) and costs, and the exploration of the uncertainty related to the impact of AEs on the economic results. ResultsWe illustrated and discussed each of the identified issues by giving health technology assessment examples. We focused on the extent to which the integration of AEs in decision models can be improved by dealing with the lack of relevant real-world safety data, estimating the consequences of AEs (eg, for costs and QoL loss), exploring the impacts of AEs that are not adequately captured in current measurement of health-related QoL, and identifying the need for development of a good terminology of relevant types of AEs to be incorporated in economic evaluation. ConclusionBased on a reflection the key methodological issues related to the incorporation of adverse drug events in economic evaluations, we suggested several recommendations to serve a starting point for health technology assessment agencies and researchers to develop good research practices in this field.
Author	Ghabri, Salah Dawoud, Dalia Drummond, Michael
Author_xml	– sequence: 1 givenname: Salah surname: Ghabri fullname: Ghabri, Salah email: s.ghabri@has-sante.fr organization: Department of Medical Evaluation, French National Authority for Health (HAS), Saint-Denis La Plaine, France – sequence: 2 givenname: Dalia surname: Dawoud fullname: Dawoud, Dalia organization: Science, Evidence and Analytics Directorate, National Institute for Health and Care Excellence (NICE), London, England, UK – sequence: 3 givenname: Michael surname: Drummond fullname: Drummond, Michael organization: Centre for Health Economics, University of York, Heslington, England, UK
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/38548180$$D View this record in MEDLINE/PubMed
BookMark	eNqFkktr3DAUhUVJybN_oIviZTd2riTL4wmlEMK0CaRkkWy6ErZ0NZVrS6lkG_LvI2eSLgJNV3pwzrmHj3tE9px3SMhHCgUFWp12RTc3fcGAlQXwAih_Rw6pYGVerjjfS3dY1zkHKg7IUYwdAFSciX1ywGtR1rSGQ_LzB46_vI6Z8SG7cqqftHXb7FzPGCJmmxndGDPrso3yzg9Wpa-mn5rRehfPsttpu8X49NglDPfBzzgk1wl5b5o-4ofn85jcfdvcXVzm1zffry7Or3NVVmzMq7ZkSggUIlWqWqPUymiqmsqotkJITQUazXjbKlgZAMONYBrWFEFwWvFj8nkXmwb_mVIXOdiosO8bh36KkgNjoqrZepWkn56lUzuglvfBDk14kC80koDtBCr4GAOavxIKckEuO7kglwtyCVwm5MlUvzIpOz7xGUNj-7etX3ZWTHxmi0FGZdEp1DagGqX29m3711d21VtnVdP_xgeMnZ-CS-QllZFJkLfLOizbwEoAymqaAs7-HfC_6Y-ilcUX
CitedBy_id	crossref_primary_10_1001_jamanetworkopen_2025_12455 crossref_primary_10_1186_s13561_025_00651_6 crossref_primary_10_2147_CEOR_S509349 crossref_primary_10_1016_j_vaccine_2025_127341
Cites_doi	10.1136/bmjqs-2017-006481 10.1186/1478-7954-4-13 10.2217/cer-2021-0059 10.1016/j.jval.2019.01.004 10.1007/s41669-021-00316-0 10.1016/j.jval.2019.09.1086 10.1007/s40273-013-0120-z 10.1007/s40258-013-0058-5 10.3310/hta20350 10.1111/jan.14860 10.1007/s40258-020-00562-z 10.1016/j.jval.2017.06.007 10.1177/0272989X10393284 10.1017/S0266462310000371 10.3346/jkms.2019.34.e255 10.1016/j.jval.2016.06.001 10.1007/s40273-022-01232-9 10.1016/j.jval.2020.12.012 10.1007/s40273-023-01252-z 10.1177/0272989X07309639 10.2147/CEOR.S115689 10.1186/s12913-018-3335-z 10.1111/add.15675 10.1002/hec.3469 10.1080/14737167.2020.1693268
ContentType	Journal Article
Copyright	2024 Copyright © 2024. Published by Elsevier Inc.
Copyright_xml	– notice: 2024 – notice: Copyright © 2024. Published by Elsevier Inc.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.jval.2024.03.013
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology Public Health
EISSN	1524-4733
EndPage	942
ExternalDocumentID	38548180 10_1016_j_jval_2024_03_013 S1098301524001281 1_s2_0_S1098301524001281
Genre	Journal Article
GroupedDBID	--- --K --M .1- .3N .FO .GA .Y3 .~1 0R~ 10A 123 1OC 1P~ 1~. 29Q 31~ 36B 4.4 44B 457 4G. 51W 51X 52N 52P 52R 52S 52X 53G 5LA 5VS 66C 6PF 7-5 7PT 8-1 8P~ 8UM AAEDT AAEDW AAFJI AAFWJ AAIKJ AAKOC AALRI AAMMB AAOAW AAPFB AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABCQN ABDBF ABEML ABIVO ABJNI ABMAC ABMMH ABMZM ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACLOT ACPRK ACRLP ACRPL ACUHS ACVFH ACXQS ADBBV ADCNI ADEZE ADFHU ADMUD ADNMO ADVLN AEBSH AEFGJ AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AEYQN AFBPY AFEBI AFJKZ AFPUW AFRHN AFTJW AFXIZ AFZJQ AGHFR AGQPQ AGTHC AGUBO AGXDD AGYEJ AIDQK AIDYY AIEXJ AIGII AIIAU AIIUN AIKHN AITUG AJAOE AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AOMHK APXCP ASPBG AVARZ AVWKF AXJTR AXLSJ AZFZN BAWUL BFHJK BKOJK BLXMC BNPGV BY8 CAG CO8 COF CS3 DCZOG DIK DU5 EAD EAP EBS EFJIC EFKBS EFLBG EJD EMB EMK EMOBN ESX F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HF~ HVGLF HZI HZ~ IHE IXB KOM LH4 M41 MO0 N9A O-L O9- OAUVE OIG OK1 OVD P-8 P-9 P2P PC. PQQKQ PRBVW Q38 QB0 R2- ROL SDF SEL SES SPCBC SSB SSF SSH SSO SSZ SV3 T5K TEORI TUS W99 WIN WYUIH XG1 YFH Z5R ~G- ~HD 0SF 6I. AACTN AAFTH AAHHS ABVKL ACCFJ AEEZP AEQDE AFCTW AFKWA AIWBW AJBDE AJOXV AMFUW NCXOZ RIG SUPJJ AAIAV AAYXX ALUQN CITATION O8X CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c462t-6b42c55e555486bfcc7fd1ca6fcb6e03855efd23bbc07f00f3f52d091e053163
ISICitedReferencesCount	3
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001261983700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1098-3015 1524-4733
IngestDate	Sun Sep 28 04:53:08 EDT 2025 Thu Apr 03 07:01:34 EDT 2025 Tue Nov 18 22:40:10 EST 2025 Sat Nov 29 07:48:13 EST 2025 Sat Jul 20 16:36:20 EDT 2024 Tue Feb 25 19:54:58 EST 2025 Tue Oct 14 19:31:01 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Keywords	health technology assessment costs Adverse events decision models disutilities economic evaluation quality of life uncertainty
Language	English
License	Copyright © 2024. Published by Elsevier Inc.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c462t-6b42c55e555486bfcc7fd1ca6fcb6e03855efd23bbc07f00f3f52d091e053163
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://www.clinicalkey.com/#!/content/1-s2.0-S1098301524001281
PMID	38548180
PQID	3022568297
PQPubID	23479
PageCount	7
ParticipantIDs	proquest_miscellaneous_3022568297 pubmed_primary_38548180 crossref_primary_10_1016_j_jval_2024_03_013 crossref_citationtrail_10_1016_j_jval_2024_03_013 elsevier_sciencedirect_doi_10_1016_j_jval_2024_03_013 elsevier_clinicalkeyesjournals_1_s2_0_S1098301524001281 elsevier_clinicalkey_doi_10_1016_j_jval_2024_03_013
PublicationCentury	2000
PublicationDate	2024-07-01
PublicationDateYYYYMMDD	2024-07-01
PublicationDate_xml	– month: 07 year: 2024 text: 2024-07-01 day: 01
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Value in health
PublicationTitleAlternate	Value Health
PublicationYear	2024
Publisher	Elsevier Inc
Publisher_xml	– name: Elsevier Inc
References	Bouée-Benhamiche, Bousquet, Ghabri (bib39) 2020; 18 Flanagan, McIntosh, Le Petit, Berthelot (bib41) 2006; 4 (bib14) 2020 bib15 bib12 Xie, Guo, Bremner, Wang, Shah, Volodin (bib44) 2021; 10 bib13 Pullenayegum, Tarride, Xie, O’Reilly (bib35) 2011; 31 bib32 Thomas, Dalili, López-López (bib31) 2022; 117 Keeney, Welton, Stevenson (bib8) 2021; 24 Howell, Matza, Jun, Garcia, Powers, Maloney (bib24) 2022; 6 bib29 Dale, Basu, Elstein, Meltzer (bib43) 2008; 28 Lu, Dai, Chang (bib23) 2023; 41 Brazier, Ara, Azzabi (bib33) 2019; 22 Heather, Payne, Harrison, Symmons (bib19) 2014; 32 Aronson (bib1) 2023 (bib28) 2019 Gyllensten, Jönsson, Hakkarainen, Svensson, Hägg, Rehnberg (bib21) 2017; 20 Tarricone, Torbica, Drummond (bib10) 2017; 26 Wang, Shi, Guan, Xu, Liu, Li (bib36) 2021; 9 Craig, McDaid, Fonseca, Stock, Duffy, Woolacott (bib18) 2010; 26 Pearce, Haas, Viney (bib37) 2013; 11 Murphy, Griffiths, Duffield (bib22) 2021; 77 Mohammed Al-Worafi (bib20) 2020 bib7 Gagliardi, Ducey, Lehoux (bib30) 2018; 27 bib5 bib6 bib3 bib16 bib38 Schwendimann, Blatter, Dhaini, Simon, Ausserhofer (bib45) 2018; 18 bib4 Yoon, Chang, Lee (bib9) 2019; 34 bib17 Batel Marques, Penedones, Mendes, Alves (bib40) 2016; 8 Stevenson, Archer, Tosh (bib27) 2016; 20 bib2 Wolowacz, Briggs, Belozeroff (bib34) 2016; 19 Basu, Eggington (bib11) 2019; 19 Lam, Ghabri (bib26) 2019; 22 Doggen, van Hoek, Luyten (bib25) 2023; 41 Ara, Brazier (bib42) 2017; 35 Brazier (10.1016/j.jval.2024.03.013_bib33) 2019; 22 Yoon (10.1016/j.jval.2024.03.013_bib9) 2019; 34 Stevenson (10.1016/j.jval.2024.03.013_bib27) 2016; 20 Doggen (10.1016/j.jval.2024.03.013_bib25) 2023; 41 Ara (10.1016/j.jval.2024.03.013_bib42) 2017; 35 Howell (10.1016/j.jval.2024.03.013_bib24) 2022; 6 Wang (10.1016/j.jval.2024.03.013_bib36) 2021; 9 Basu (10.1016/j.jval.2024.03.013_bib11) 2019; 19 Bouée-Benhamiche (10.1016/j.jval.2024.03.013_bib39) 2020; 18 Pullenayegum (10.1016/j.jval.2024.03.013_bib35) 2011; 31 Heather (10.1016/j.jval.2024.03.013_bib19) 2014; 32 Lu (10.1016/j.jval.2024.03.013_bib23) 2023; 41 Murphy (10.1016/j.jval.2024.03.013_bib22) 2021; 77 Dale (10.1016/j.jval.2024.03.013_bib43) 2008; 28 Thomas (10.1016/j.jval.2024.03.013_bib31) 2022; 117 Mohammed Al-Worafi (10.1016/j.jval.2024.03.013_bib20) 2020 Gagliardi (10.1016/j.jval.2024.03.013_bib30) 2018; 27 Xie (10.1016/j.jval.2024.03.013_bib44) 2021; 10 Tarricone (10.1016/j.jval.2024.03.013_bib10) 2017; 26 Schwendimann (10.1016/j.jval.2024.03.013_bib45) 2018; 18 Keeney (10.1016/j.jval.2024.03.013_bib8) 2021; 24 Pearce (10.1016/j.jval.2024.03.013_bib37) 2013; 11 Flanagan (10.1016/j.jval.2024.03.013_bib41) 2006; 4 Batel Marques (10.1016/j.jval.2024.03.013_bib40) 2016; 8 Wolowacz (10.1016/j.jval.2024.03.013_bib34) 2016; 19 Craig (10.1016/j.jval.2024.03.013_bib18) 2010; 26 Lam (10.1016/j.jval.2024.03.013_bib26) 2019; 22 Gyllensten (10.1016/j.jval.2024.03.013_bib21) 2017; 20 Aronson (10.1016/j.jval.2024.03.013_bib1) 2023
References_xml	– volume: 6 start-page: 367 year: 2022 end-page: 376 ident: bib24 article-title: Health state utilities for adverse events associated with chimeric antigen receptor T-cell therapy in large B-cell lymphoma publication-title: Pharmacoecon Open – volume: 11 start-page: 619 year: 2013 end-page: 637 ident: bib37 article-title: Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review publication-title: Appl Health Econ Health Policy – ident: bib3 article-title: Guidance for Industry. Benefit-risk assessment for new drug and biological products – ident: bib7 article-title: Genvoya® (elvitegravir 150 mg / cobicistat 150 mg / emtricitabine 200 mg / ténofovir alafénamide 10 mg) – ident: bib16 article-title: Guidelines for the Economic Evaluation of Health Technologies: Canada-4th Edition December 2017. Canada Drug and Health Technology Agency – volume: 41 start-page: 481 year: 2023 end-page: 497 ident: bib25 article-title: Accounting for adverse events following immunization in economic evaluation: systematic review of economic evaluations of pediatric vaccines against pneumococcus, rotavirus, human papillomavirus, meningococcus and measles-mumps-rubella-varicella publication-title: Pharmacoeconomics – volume: 32 start-page: 109 year: 2014 end-page: 134 ident: bib19 article-title: Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models publication-title: Pharmacoeconomics – volume: 41 start-page: 295 year: 2023 end-page: 306 ident: bib23 article-title: Whether and how disutilities of adverse events were used in the economic evaluation of drug therapy for cancer treatment publication-title: Pharmacoeconomics – volume: 26 start-page: 5 year: 2017 end-page: 12 ident: bib10 article-title: Challenges in the assessment of medical devices: the MedtecHTA project publication-title: Health Econ – ident: bib15 article-title: Guidelines for preparing a submission to the pharmaceutical benefits advisory committee. Australian Government. Version 5.0 – ident: bib38 article-title: WHO. ICD-10 version 2019 – volume: 22 start-page: 267 year: 2019 end-page: 275 ident: bib33 article-title: Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force report publication-title: Value Health – volume: 28 start-page: 102 year: 2008 end-page: 112 ident: bib43 article-title: Predicting utility ratings for joint health states from single health states in prostate cancer: empirical testing of 3 alternative theories publication-title: Med Decis Mak – volume: 19 start-page: 704 year: 2016 end-page: 719 ident: bib34 article-title: Estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force report publication-title: Value Health – ident: bib2 article-title: European Medicines Agency. Benefit-risk methodology – volume: 26 start-page: 323 year: 2010 end-page: 329 ident: bib18 article-title: Are adverse effects incorporated in economic models? A survey of current practice publication-title: Int J Technol Assess Health Care – ident: bib5 article-title: Économique Wegovy – ident: bib32 article-title: Section 4.8: Undesirable effects – volume: 20 start-page: 1299 year: 2017 end-page: 1310 ident: bib21 article-title: Comparing methods for estimating direct costs of adverse drug events publication-title: Value Health – volume: 8 start-page: 413 year: 2016 end-page: 426 ident: bib40 article-title: A systematic review of observational studies evaluating costs of adverse drug reactions publication-title: Clinicoecon Outcomes Res – ident: bib13 article-title: NICE health technology evaluations: the manual – volume: 4 start-page: 13 year: 2006 ident: bib41 article-title: Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores publication-title: Popul Health Metr – year: 2019 ident: bib28 article-title: Évaluation médico-économique des traitements de fond biologiques dans la prise en charge de la polyarthrite rhumatoïde – volume: 18 start-page: 521 year: 2018 ident: bib45 article-title: The occurrence, types, consequences and preventability of in-hospital adverse events–a scoping review publication-title: BMC Health Serv Res – year: 2020 ident: bib14 article-title: Choices in methods for economic evaluation – ident: bib6 article-title: Keytruda® (pembrolizumab) en association à Inlyta – ident: bib17 article-title: Belgian Guidelines for Economic Evaluation and Budget Impact Analyses: second edition. KCE – volume: 9 year: 2021 ident: bib36 article-title: A systematic review of methods and study quality of economic evaluations for the treatment of schizophrenia publication-title: Front Public Health – volume: 77 start-page: 3379 year: 2021 end-page: 3388 ident: bib22 article-title: Estimating the economic cost of nurse sensitive adverse events amongst patients in medical and surgical settings publication-title: J Adv Nurs – volume: 18 start-page: 491 year: 2020 end-page: 508 ident: bib39 article-title: Economic evaluations of anticancer drugs based on medico-administrative databases: a systematic literature review publication-title: Appl Health Econ Health Policy – volume: 20 start-page: 1 year: 2016 end-page: 610 ident: bib27 article-title: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation publication-title: Health Technol Assess – volume: 10 start-page: 961 year: 2021 end-page: 974 ident: bib44 article-title: Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes publication-title: J Comp Eff Res – volume: 35 year: 2017 ident: bib42 article-title: Estimating health state utility values for comorbidities publication-title: Pharmacoeconomics – volume: 19 start-page: 619 year: 2019 end-page: 626 ident: bib11 article-title: Intrinsic properties of medical devices: considerations for economic evaluation publication-title: Expert Rev Pharmacoecon Outcomes Res – ident: bib12 article-title: WHO Guide for Standardization of Economic Evaluations of Immunization Programmes. 2nd ed – volume: 34 start-page: e255 year: 2019 ident: bib9 article-title: Differences in perspectives of medical device adverse events: observational results in training program using virtual cases publication-title: J Korean Med Sci – volume: 31 start-page: 790 year: 2011 end-page: 799 ident: bib35 article-title: Calculating utility decrements associated with an adverse event: marginal Tobit and CLAD coefficients should be used with caution publication-title: Med Decis Mak – volume: 117 start-page: 861 year: 2022 end-page: 876 ident: bib31 article-title: Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials publication-title: Addiction – ident: bib29 article-title: Evidence Gaps for drugs and medical devices at market entry in Europe and potential solutions – start-page: 381 year: 2023 end-page: 917 ident: bib1 article-title: When I use a word…..medical definitions: adverse events, effects and reactions publication-title: BMJ – volume: 24 start-page: 780 year: 2021 end-page: 788 ident: bib8 article-title: Cost-effectiveness analysis of Smoking Cessation interventions in the United Kingdom accounting for major neuropsychiatric adverse events publication-title: Value Health – volume: 22 start-page: S609 year: 2019 ident: bib26 article-title: Inclusion of adverse events in the economic evaluation of health technologies: a review of the manufacturers in the economic evaluation of health technologies: a review of the manufacturers’ submissions to the French national authority for health (HAS) publication-title: Value Health – volume: 27 start-page: 190 year: 2018 end-page: 198 ident: bib30 article-title: Factors influencing the reporting of adverse medical device events: qualitative interviews with physicians about higher risk implantable devices publication-title: BMJ Qual Saf – ident: bib4 article-title: Lecanemab for early Alzheimer’s disease: final evidence report – start-page: 187 year: 2020 end-page: 195 ident: bib20 article-title: Chapter 16. Medications safety pharmacoeconomics related issues publication-title: Drug Safety in Developing Countries – start-page: 187 year: 2020 ident: 10.1016/j.jval.2024.03.013_bib20 article-title: Chapter 16. Medications safety pharmacoeconomics related issues – volume: 27 start-page: 190 issue: 3 year: 2018 ident: 10.1016/j.jval.2024.03.013_bib30 article-title: Factors influencing the reporting of adverse medical device events: qualitative interviews with physicians about higher risk implantable devices publication-title: BMJ Qual Saf doi: 10.1136/bmjqs-2017-006481 – volume: 4 start-page: 13 issue: 1 year: 2006 ident: 10.1016/j.jval.2024.03.013_bib41 article-title: Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores publication-title: Popul Health Metr doi: 10.1186/1478-7954-4-13 – volume: 10 start-page: 961 issue: 13 year: 2021 ident: 10.1016/j.jval.2024.03.013_bib44 article-title: Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes publication-title: J Comp Eff Res doi: 10.2217/cer-2021-0059 – volume: 22 start-page: 267 issue: 3 year: 2019 ident: 10.1016/j.jval.2024.03.013_bib33 article-title: Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force report publication-title: Value Health doi: 10.1016/j.jval.2019.01.004 – volume: 9 year: 2021 ident: 10.1016/j.jval.2024.03.013_bib36 article-title: A systematic review of methods and study quality of economic evaluations for the treatment of schizophrenia publication-title: Front Public Health – volume: 6 start-page: 367 issue: 3 year: 2022 ident: 10.1016/j.jval.2024.03.013_bib24 article-title: Health state utilities for adverse events associated with chimeric antigen receptor T-cell therapy in large B-cell lymphoma publication-title: Pharmacoecon Open doi: 10.1007/s41669-021-00316-0 – volume: 22 start-page: S609 year: 2019 ident: 10.1016/j.jval.2024.03.013_bib26 article-title: Inclusion of adverse events in the economic evaluation of health technologies: a review of the manufacturers in the economic evaluation of health technologies: a review of the manufacturers’ submissions to the French national authority for health (HAS) publication-title: Value Health doi: 10.1016/j.jval.2019.09.1086 – volume: 32 start-page: 109 issue: 2 year: 2014 ident: 10.1016/j.jval.2024.03.013_bib19 article-title: Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models publication-title: Pharmacoeconomics doi: 10.1007/s40273-013-0120-z – volume: 11 start-page: 619 issue: 6 year: 2013 ident: 10.1016/j.jval.2024.03.013_bib37 article-title: Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review publication-title: Appl Health Econ Health Policy doi: 10.1007/s40258-013-0058-5 – volume: 20 start-page: 1 issue: 35 year: 2016 ident: 10.1016/j.jval.2024.03.013_bib27 publication-title: Health Technol Assess doi: 10.3310/hta20350 – volume: 77 start-page: 3379 issue: 8 year: 2021 ident: 10.1016/j.jval.2024.03.013_bib22 article-title: Estimating the economic cost of nurse sensitive adverse events amongst patients in medical and surgical settings publication-title: J Adv Nurs doi: 10.1111/jan.14860 – start-page: 381 year: 2023 ident: 10.1016/j.jval.2024.03.013_bib1 article-title: When I use a word…..medical definitions: adverse events, effects and reactions publication-title: BMJ – volume: 18 start-page: 491 issue: 4 year: 2020 ident: 10.1016/j.jval.2024.03.013_bib39 article-title: Economic evaluations of anticancer drugs based on medico-administrative databases: a systematic literature review publication-title: Appl Health Econ Health Policy doi: 10.1007/s40258-020-00562-z – volume: 20 start-page: 1299 issue: 10 year: 2017 ident: 10.1016/j.jval.2024.03.013_bib21 article-title: Comparing methods for estimating direct costs of adverse drug events publication-title: Value Health doi: 10.1016/j.jval.2017.06.007 – volume: 31 start-page: 790 issue: 6 year: 2011 ident: 10.1016/j.jval.2024.03.013_bib35 article-title: Calculating utility decrements associated with an adverse event: marginal Tobit and CLAD coefficients should be used with caution publication-title: Med Decis Mak doi: 10.1177/0272989X10393284 – volume: 26 start-page: 323 issue: 3 year: 2010 ident: 10.1016/j.jval.2024.03.013_bib18 article-title: Are adverse effects incorporated in economic models? A survey of current practice publication-title: Int J Technol Assess Health Care doi: 10.1017/S0266462310000371 – volume: 34 start-page: e255 issue: 39 year: 2019 ident: 10.1016/j.jval.2024.03.013_bib9 article-title: Differences in perspectives of medical device adverse events: observational results in training program using virtual cases publication-title: J Korean Med Sci doi: 10.3346/jkms.2019.34.e255 – volume: 19 start-page: 704 issue: 6 year: 2016 ident: 10.1016/j.jval.2024.03.013_bib34 article-title: Estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force report publication-title: Value Health doi: 10.1016/j.jval.2016.06.001 – volume: 41 start-page: 295 issue: 3 year: 2023 ident: 10.1016/j.jval.2024.03.013_bib23 article-title: Whether and how disutilities of adverse events were used in the economic evaluation of drug therapy for cancer treatment publication-title: Pharmacoeconomics doi: 10.1007/s40273-022-01232-9 – volume: 24 start-page: 780 issue: 6 year: 2021 ident: 10.1016/j.jval.2024.03.013_bib8 article-title: Cost-effectiveness analysis of Smoking Cessation interventions in the United Kingdom accounting for major neuropsychiatric adverse events publication-title: Value Health doi: 10.1016/j.jval.2020.12.012 – volume: 41 start-page: 481 issue: 5 year: 2023 ident: 10.1016/j.jval.2024.03.013_bib25 article-title: Accounting for adverse events following immunization in economic evaluation: systematic review of economic evaluations of pediatric vaccines against pneumococcus, rotavirus, human papillomavirus, meningococcus and measles-mumps-rubella-varicella publication-title: Pharmacoeconomics doi: 10.1007/s40273-023-01252-z – volume: 28 start-page: 102 issue: 1 year: 2008 ident: 10.1016/j.jval.2024.03.013_bib43 article-title: Predicting utility ratings for joint health states from single health states in prostate cancer: empirical testing of 3 alternative theories publication-title: Med Decis Mak doi: 10.1177/0272989X07309639 – volume: 8 start-page: 413 year: 2016 ident: 10.1016/j.jval.2024.03.013_bib40 article-title: A systematic review of observational studies evaluating costs of adverse drug reactions publication-title: Clinicoecon Outcomes Res doi: 10.2147/CEOR.S115689 – volume: 18 start-page: 521 issue: 1 year: 2018 ident: 10.1016/j.jval.2024.03.013_bib45 article-title: The occurrence, types, consequences and preventability of in-hospital adverse events–a scoping review publication-title: BMC Health Serv Res doi: 10.1186/s12913-018-3335-z – volume: 117 start-page: 861 issue: 4 year: 2022 ident: 10.1016/j.jval.2024.03.013_bib31 article-title: Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials publication-title: Addiction doi: 10.1111/add.15675 – volume: 26 start-page: 5 issue: suppl 1 year: 2017 ident: 10.1016/j.jval.2024.03.013_bib10 article-title: Challenges in the assessment of medical devices: the MedtecHTA project publication-title: Health Econ doi: 10.1002/hec.3469 – volume: 19 start-page: 619 issue: 6 year: 2019 ident: 10.1016/j.jval.2024.03.013_bib11 article-title: Intrinsic properties of medical devices: considerations for economic evaluation publication-title: Expert Rev Pharmacoecon Outcomes Res doi: 10.1080/14737167.2020.1693268 – volume: 35 issue: suppl 1 year: 2017 ident: 10.1016/j.jval.2024.03.013_bib42 article-title: Estimating health state utility values for comorbidities publication-title: Pharmacoeconomics
SSID	ssj0006325
Score	2.4237175
Snippet	Inclusion of relevant effectiveness and safety outcomes in economic evaluation of health technologies is required to aid efficient healthcare decisions. Our... AbstractObjectiveInclusion of relevant effectiveness and safety outcomes in economic evaluation of health technologies is required to aid efficient healthcare...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	936
SubjectTerms	Adverse events Cost-Benefit Analysis - methods costs decision models Decision Support Techniques disutilities Drug-Related Side Effects and Adverse Reactions - economics economic evaluation health technology assessment Humans Internal Medicine Models, Economic Public Health Quality of Life Technology Assessment, Biomedical Terminology as Topic Uncertainty
Title	Methods for Including Adverse Events in Economic Evaluations: Suggestions for Improvement
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1098301524001281 https://www.clinicalkey.es/playcontent/1-s2.0-S1098301524001281 https://dx.doi.org/10.1016/j.jval.2024.03.013 https://www.ncbi.nlm.nih.gov/pubmed/38548180 https://www.proquest.com/docview/3022568297
Volume	27
WOSCitedRecordID	wos001261983700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1524-4733 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006325 issn: 1098-3015 databaseCode: AIEXJ dateStart: 20210201 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZYhxAvCMatXCYjob5sqXJzLrxNrBOgrVRqQOXJShwbWlXpaNqx_XuOL3GqsY3xwEtUWbGd-ny2j32-cw5Cb4uUJWlceE4u1beQl66TF0HkSDqlgO0qKnmikk3Ew2EymaQjQxurVTqBuKqS8_P09L-KGspA2NJ19h_EbRuFAvgNQocniB2etxL8icoJrcIsyNk_Xyu3FZV4ueZ7gzPl0jatrEsyFDUBvxU9brz-Lm1OiiCn2lDXDi1DxmiyX6GSCjiiPSktj-dHXmjn9XE-b--aD_Nfi7Uh0c-ndis4XKqBKS8T-M01hB9ayqpdOaEsjHVUiz6_oswstzoUgIFVvLF2pjoSyh9rur5emPVnMBp92bWKSusF7Q7WWO2Hn-nRl-Njmg0mWe_0pyNzi0kbvEm0soW2_ZikSQdtH3wcTD7ZHTsKVHJe-7nGuUrzAC93e50Cc90BRSkq2UP0wJww8IFGxiN0h1c76N6J4VDsoN5IRyu_2MdZ63xX7-MeHrVxzC8eo28GSRhQgC2SsEES1kjC0wo3SMIbSHqHN3CkW2hx9ARlR4Ps_QfHZOJwWBj5KycqQp8Rwgkon0lUCMZiUXosjwQrIi6Ny4SL0g-KgrmxcF0RCOKXoIrKxCOg8T9FnWpR8ecIE5IHHI7IOQ9ZCKpxIcqIiUBau-F9wbvIa0aXMhOlXiZLmdOGjjijUiJUSoS6AQWJdNGerXOqY7Tc-HbQCI023sewX1KA24214qtq8drM_Jp6tPapS8eemyawaxJJzpZm6i4itqbRarW2-tce3zSIorDkSzteXvHFuqYB6N0kkj7xXfRMQ83-bxBFKMM3vLhF7ZfofjuTX6HOarnmr9Fddraa1stdtBVPkl0zVX4D8zPX1A
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Methods+for+Including+Adverse+Events+in+Economic+Evaluations%3A+Suggestions+for+Improvement&rft.jtitle=Value+in+health&rft.au=Ghabri%2C+Salah&rft.au=Dawoud%2C+Dalia&rft.au=Drummond%2C+Michael&rft.date=2024-07-01&rft.issn=1524-4733&rft.eissn=1524-4733&rft.volume=27&rft.issue=7&rft.spage=936&rft_id=info:doi/10.1016%2Fj.jval.2024.03.013&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-3015&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-3015&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-3015&client=summon